Improving	O
vascular	B:C1621275
maturation	I:C1621275
using	O
noncoding	O
RNAs	I:C0887909
increases	O
antitumor	O
effect	O
of	O
chemotherapy	O
.	O

Improving	O
vascular	O
maturation	I:C1621275
using	O
noncoding	B:C0887909
RNAs	I:C0887909
increases	O
antitumor	O
effect	O
of	O
chemotherapy	O
.	O

Improving	O
vascular	O
maturation	I:C1621275
using	O
noncoding	O
RNAs	I:C0887909
increases	O
antitumor	O
effect	O
of	O
chemotherapy	B:C3665472
.	O

Current	O
antiangiogenesis	B:C0281318
therapy	I:C0281318
relies	O
on	O
inhibiting	O
newly	O
developed	O
immature	O
tumor	O
blood	I:C0027668
vessels	I:C0027668
and	O
starving	O
tumor	O
cells	I:C0597032
.	O

Current	O
antiangiogenesis	O
therapy	I:C0281318
relies	O
on	O
inhibiting	O
newly	O
developed	O
immature	O
tumor	B:C0027668
blood	I:C0027668
vessels	I:C0027668
and	O
starving	O
tumor	O
cells	I:C0597032
.	O

Current	O
antiangiogenesis	O
therapy	I:C0281318
relies	O
on	O
inhibiting	O
newly	O
developed	O
immature	O
tumor	O
blood	I:C0027668
vessels	I:C0027668
and	O
starving	O
tumor	B:C0597032
cells	I:C0597032
.	O

Here	O
,	O
we	O
report	O
a	O
better	O
approach	O
to	O
target	O
cancer	B:C0006826
-	O
associated	O
endothelial	O
cells	I:C0225336
(	O
endothelial	O
cells	I:C0225336
)	O
,	O
reverse	O
permeability	O
and	O
leakiness	O
of	O
tumor	O
blood	I:C0027668
vessels	I:C0027668
,	O
and	O
improve	O
delivery	O
of	O
chemotherapeutic	O
agents	I:C0729502
to	O
the	O
tumor	O
.	O

Here	O
,	O
we	O
report	O
a	O
better	O
approach	O
to	O
target	O
cancer	O
-	O
associated	O
endothelial	B:C0225336
cells	I:C0225336
(	O
endothelial	O
cells	I:C0225336
)	O
,	O
reverse	O
permeability	O
and	O
leakiness	O
of	O
tumor	O
blood	I:C0027668
vessels	I:C0027668
,	O
and	O
improve	O
delivery	O
of	O
chemotherapeutic	O
agents	I:C0729502
to	O
the	O
tumor	O
.	O

Here	O
,	O
we	O
report	O
a	O
better	O
approach	O
to	O
target	O
cancer	O
-	O
associated	O
endothelial	O
cells	I:C0225336
(	O
endothelial	B:C0225336
cells	I:C0225336
)	O
,	O
reverse	O
permeability	O
and	O
leakiness	O
of	O
tumor	O
blood	I:C0027668
vessels	I:C0027668
,	O
and	O
improve	O
delivery	O
of	O
chemotherapeutic	O
agents	I:C0729502
to	O
the	O
tumor	O
.	O

Here	O
,	O
we	O
report	O
a	O
better	O
approach	O
to	O
target	O
cancer	O
-	O
associated	O
endothelial	O
cells	I:C0225336
(	O
endothelial	O
cells	I:C0225336
)	O
,	O
reverse	O
permeability	O
and	O
leakiness	O
of	O
tumor	B:C0027668
blood	I:C0027668
vessels	I:C0027668
,	O
and	O
improve	O
delivery	O
of	O
chemotherapeutic	O
agents	I:C0729502
to	O
the	O
tumor	O
.	O

Here	O
,	O
we	O
report	O
a	O
better	O
approach	O
to	O
target	O
cancer	O
-	O
associated	O
endothelial	O
cells	I:C0225336
(	O
endothelial	O
cells	I:C0225336
)	O
,	O
reverse	O
permeability	O
and	O
leakiness	O
of	O
tumor	O
blood	I:C0027668
vessels	I:C0027668
,	O
and	O
improve	O
delivery	O
of	O
chemotherapeutic	B:C0729502
agents	I:C0729502
to	O
the	O
tumor	O
.	O

Here	O
,	O
we	O
report	O
a	O
better	O
approach	O
to	O
target	O
cancer	O
-	O
associated	O
endothelial	O
cells	I:C0225336
(	O
endothelial	O
cells	I:C0225336
)	O
,	O
reverse	O
permeability	O
and	O
leakiness	O
of	O
tumor	O
blood	I:C0027668
vessels	I:C0027668
,	O
and	O
improve	O
delivery	O
of	O
chemotherapeutic	O
agents	I:C0729502
to	O
the	O
tumor	B:C0027651
.	O

First	O
,	O
we	O
identified	O
deregulated	O
microRNAs	B:C1101610
(	O
microRNAs	O
)	O
from	O
patient	O
-	O
derived	O
cancer	O
-	O
associated	O
endothelial	O
cells	I:C0225336
.	O

First	O
,	O
we	O
identified	O
deregulated	O
microRNAs	O
(	O
microRNAs	B:C1101610
)	O
from	O
patient	O
-	O
derived	O
cancer	O
-	O
associated	O
endothelial	O
cells	I:C0225336
.	O

First	O
,	O
we	O
identified	O
deregulated	O
microRNAs	O
(	O
microRNAs	O
)	O
from	O
patient	O
-	O
derived	O
cancer	B:C0006826
-	O
associated	O
endothelial	O
cells	I:C0225336
.	O

First	O
,	O
we	O
identified	O
deregulated	O
microRNAs	O
(	O
microRNAs	O
)	O
from	O
patient	O
-	O
derived	O
cancer	O
-	O
associated	O
endothelial	B:C0225336
cells	I:C0225336
.	O

Silencing	B:C0598496
these	O
microRNAs	O
led	O
to	O
decreased	O
vascular	O
permeability	I:C0162337
and	O
increased	O
maturation	O
of	I:C1621275
blood	I:C1621275
vessels	I:C1621275
.	O

Silencing	O
these	O
microRNAs	B:C1101610
led	O
to	O
decreased	O
vascular	O
permeability	I:C0162337
and	O
increased	O
maturation	O
of	I:C1621275
blood	I:C1621275
vessels	I:C1621275
.	O

Silencing	O
these	O
microRNAs	O
led	O
to	O
decreased	O
vascular	B:C0162337
permeability	I:C0162337
and	O
increased	O
maturation	O
of	I:C1621275
blood	I:C1621275
vessels	I:C1621275
.	O

Silencing	O
these	O
microRNAs	O
led	O
to	O
decreased	O
vascular	O
permeability	I:C0162337
and	O
increased	O
maturation	B:C1621275
of	I:C1621275
blood	I:C1621275
vessels	I:C1621275
.	O

Next	O
,	O
we	O
screened	B:C1710032
a	O
thioaptamer	O
(	O
thioaptamer	O
)	O
library	O
to	O
identify	O
TAs	O
selective	O
for	O
tumor	O
-	O
associated	O
endothelial	O
cells	I:C0225336
.	O

Next	O
,	O
we	O
screened	O
a	O
thioaptamer	B:C0599013
(	O
thioaptamer	O
)	O
library	O
to	O
identify	O
TAs	O
selective	O
for	O
tumor	O
-	O
associated	O
endothelial	O
cells	I:C0225336
.	O

Next	O
,	O
we	O
screened	O
a	O
thioaptamer	O
(	O
thioaptamer	B:C0599013
)	O
library	O
to	O
identify	O
TAs	O
selective	O
for	O
tumor	O
-	O
associated	O
endothelial	O
cells	I:C0225336
.	O

Next	O
,	O
we	O
screened	O
a	O
thioaptamer	O
(	O
thioaptamer	O
)	O
library	B:C0017272
to	O
identify	O
TAs	O
selective	O
for	O
tumor	O
-	O
associated	O
endothelial	O
cells	I:C0225336
.	O

Next	O
,	O
we	O
screened	O
a	O
thioaptamer	O
(	O
thioaptamer	O
)	O
library	O
to	O
identify	O
TAs	B:C0599013
selective	O
for	O
tumor	O
-	O
associated	O
endothelial	O
cells	I:C0225336
.	O

Next	O
,	O
we	O
screened	O
a	O
thioaptamer	O
(	O
thioaptamer	O
)	O
library	O
to	O
identify	O
TAs	O
selective	O
for	O
tumor	B:C0027651
-	O
associated	O
endothelial	O
cells	I:C0225336
.	O

Next	O
,	O
we	O
screened	O
a	O
thioaptamer	O
(	O
thioaptamer	O
)	O
library	O
to	O
identify	O
TAs	O
selective	O
for	O
tumor	O
-	O
associated	O
endothelial	B:C0225336
cells	I:C0225336
.	O

An	O
annexin	B:C0103404
A2	I:C0103404
-	O
targeted	O
thioaptamer	O
was	O
identified	O
and	O
used	O
for	O
delivery	O
of	O
miR106	O
b	I:C1101610
-	I:C1101610
5	I:C1101610
p	I:C1101610
and	O
miR30c	O
-	I:C1101610
5	I:C1101610
p	I:C1101610
inhibitors	O
,	O
resulting	O
in	O
vascular	O
maturation	O
and	O
antitumor	O
effects	O
without	O
inducing	O
hypoxia	O
.	O

An	O
annexin	O
A2	I:C0103404
-	O
targeted	O
thioaptamer	B:C0599013
was	O
identified	O
and	O
used	O
for	O
delivery	O
of	O
miR106	O
b	I:C1101610
-	I:C1101610
5	I:C1101610
p	I:C1101610
and	O
miR30c	O
-	I:C1101610
5	I:C1101610
p	I:C1101610
inhibitors	O
,	O
resulting	O
in	O
vascular	O
maturation	O
and	O
antitumor	O
effects	O
without	O
inducing	O
hypoxia	O
.	O

An	O
annexin	O
A2	I:C0103404
-	O
targeted	O
thioaptamer	O
was	O
identified	O
and	O
used	O
for	O
delivery	O
of	O
miR106	B:C1101610
b	I:C1101610
-	I:C1101610
5	I:C1101610
p	I:C1101610
and	O
miR30c	O
-	I:C1101610
5	I:C1101610
p	I:C1101610
inhibitors	O
,	O
resulting	O
in	O
vascular	O
maturation	O
and	O
antitumor	O
effects	O
without	O
inducing	O
hypoxia	O
.	O

An	O
annexin	O
A2	I:C0103404
-	O
targeted	O
thioaptamer	O
was	O
identified	O
and	O
used	O
for	O
delivery	O
of	O
miR106	O
b	I:C1101610
-	I:C1101610
5	I:C1101610
p	I:C1101610
and	O
miR30c	B:C1101610
-	I:C1101610
5	I:C1101610
p	I:C1101610
inhibitors	O
,	O
resulting	O
in	O
vascular	O
maturation	O
and	O
antitumor	O
effects	O
without	O
inducing	O
hypoxia	O
.	O

An	O
annexin	O
A2	I:C0103404
-	O
targeted	O
thioaptamer	O
was	O
identified	O
and	O
used	O
for	O
delivery	O
of	O
miR106	O
b	I:C1101610
-	I:C1101610
5	I:C1101610
p	I:C1101610
and	O
miR30c	O
-	I:C1101610
5	I:C1101610
p	I:C1101610
inhibitors	O
,	O
resulting	O
in	O
vascular	B:C0005847
maturation	O
and	O
antitumor	O
effects	O
without	O
inducing	O
hypoxia	O
.	O

An	O
annexin	O
A2	I:C0103404
-	O
targeted	O
thioaptamer	O
was	O
identified	O
and	O
used	O
for	O
delivery	O
of	O
miR106	O
b	I:C1101610
-	I:C1101610
5	I:C1101610
p	I:C1101610
and	O
miR30c	O
-	I:C1101610
5	I:C1101610
p	I:C1101610
inhibitors	O
,	O
resulting	O
in	O
vascular	O
maturation	B:C0678723
and	O
antitumor	O
effects	O
without	O
inducing	O
hypoxia	O
.	O

An	O
annexin	O
A2	I:C0103404
-	O
targeted	O
thioaptamer	O
was	O
identified	O
and	O
used	O
for	O
delivery	O
of	O
miR106	O
b	I:C1101610
-	I:C1101610
5	I:C1101610
p	I:C1101610
and	O
miR30c	O
-	I:C1101610
5	I:C1101610
p	I:C1101610
inhibitors	O
,	O
resulting	O
in	O
vascular	O
maturation	O
and	O
antitumor	O
effects	O
without	O
inducing	O
hypoxia	B:C0242184
.	O

These	O
findings	B:C0243095
could	O
have	O
implications	O
for	O
improving	O
vascular	O
-	O
targeted	O
therapy	O
.	O

These	O
findings	O
could	O
have	O
implications	O
for	O
improving	O
vascular	B:C0005847
-	O
targeted	O
therapy	O
.	O

